Myocarditis and inflammatory cardiomyopathy

Česká verzia

Authors: Dalibor Mlejnek; Jan Krejčí
Authors place of work: I. interní kardio-angiologická klinika LF MU a FN u sv. Anny v Brně
Published in the journal: Vnitř Lék 2017; 63(7-8): 507-512
Category: Reviews

Summary

Myocarditis is an inflammation of the heart muscle. The most common cause of myocarditis is viral infection in industrialized countries. Myocarditis with left ventricular dysfunction is called inflammatory cardiomyopathy and is the major cause of dilated cardiomyopathy. The clinical picture is very diverse, most often the patient present with signs of heart failure, arrhythmic symptoms and chest pains. Despite significant advances in non-invasive diagnostics, particularly magnetic resonance imaging, endomyocardial biopsy remains the gold standard of myocarditis diagnosis. Myocarditis and inflammatory cardiomyopathy therapy is primarily based on the restriction of physical activity and the pharmacotherapy of heart failure. Specific treatment – immunosuppressive or antimicrobial – may be considered in some cases according to endomyocardial biopsy results. Implantation of mechanical cardiac support or heart transplantation is indicated only in the most serious cases.

Key words:
clinical course – diagnostics – inflammatory cardiomyopathy – myocarditis – treatment

Zdroje

1. Richardson P, McKenna W, Bristow M et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93(5): 841–842.

2. Breinhold JP, Moulik M, Dreyer WJ et al. Viral epidemiologic shift in inflammatory heart disease: the increasing involvement of parvovirus B19 in the myocardium of pediatric cardiac transplant patients. J Heart Lung Transplant 2010; 29(7): 739–746. Dostupné z DOI: <http://dx.doi.org/10.1016/j.healun.2010.03.003>.

3. Palecek T, Kuchynka P, Hulinska D et al. Presence of Borrelia burgdorferi in endomyocardial biopsies in patients with new-onset unexplained dilated cardiomyopathy. Med Microbiol Immunol 2010; 199(2): 139–143. Dostupné z DOI: <http://dx.doi.org/10.1007/s00430–009–0141–6>.

4. Kubanek M, Sramko M, Berenova D et al. Detection of Borrelia burgdorferi sensu lato in endomyocardial biopsy specimens in individuals with recent-onset dilated cardiomyopathy. Eur J Heart Fail 2012; 14(6): 588–596. Dostupné z DOI: <http://dx.doi.org/10.1093/eurjhf/hfs027>.

5. Malik LH, Singh GD, Amsterdam EA. The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease. Clin Cardiol 2015; 38(9): 565–569. Dostupné z DOI: <http://dx.doi.org/10.1002/clc.22421>.

6. Cooper LT. Myocarditis. N Engl J Med 2009; 360(15): 1526–1538. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMra0800028>.

7. Kindermann I, Barth C, Mahfoud F et al. Update on myocarditis. J Am Coll Cardiol 2012; 59(9): 779–792. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2011.09.074>.

8. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J 2008; 29(17): 2073–2082. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehn296>.

9. Schultheiss HP, Kühl U, Cooper LT. The management of myocarditis. Eur Heart J 2011; 32(21): 2616–2625. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehr165>.

10. D’Ambrosio A, Patti G, Manzoli A et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001; 85(5): 499–504.

11. Caforio ALP, Pankuweit S, Arbustini E et al. Current state of knowledge on ethiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34(33): 2636–2648, 2648a-2648d. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/eht210>.

12. Kühl U, Pauschinger M, Noutsias M et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with „idiopathic“ left ventricular dysfunction. Circulation 2005; 111(7): 887–893.

13. Krejci J, Poloczkova H, Hude P et al. Impact of inflammatory infiltration and viral genome presence in myocardium on the changes of echocardiographic parameters. Cor et Vasa 2013; 55(4): e333-e340. Dostupné z DOI: <https://doi.org/10.1016/j.crvasa.2013.02.003>.

14. Kuethe F, Lindner J, Matschke K et al. Prevalence of parvovirus B19 and human bocavirus DNA in the heart of patients with no evidence of dilated cardiomyopathy or myocarditis. Clin Infect Dis 2009; 49(11): 1660–1666. Dostupné z DOI: <http://dx.doi.org/10.1086/648074>.

15. Caforio ALP, Calabrese F, Angelini A et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007; 28(11): 1326–1333.

16. Kühl U, Lassner D, von Schlippenbach J et al. Interferon-beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol 2012; 60(14): 1295–1296. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.06.026>.

17. Kindermann I, Kindermann M, Kandolf R et al. Predictors of outcome in patients with suspected myocarditis. Circulation 2008; 118(6): 639–648. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.108.769489>.

18. Philips M, Robinowitz M, Higgins JR et al. Sudden cardiac death in Air Force recruits. A 20-year review. JAMA 1986; 256(19): 2696–2699.

19. Mason JW, O´Connell JB, Herskowitz A et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333(5): 269–275.

20. Krejci J, Mlejnek D, Sochorova D et al. Inflammatory Cardiomyopathy: A Current View on the Pathophysiology, Diagnosis, and Treatment. Biomed Res Int 2016; 2016: 4087632. Dostupné z DOI: <http://dx.doi.org/10.1155/2016/4087632>.

21. Friedrich MG, Sechtem U, Schulz-Menger J et al. Cardiovascular magnetic resonance in myocarditis: a JACC White paper. J Am Coll Cardiol 2009; 53(17): 1475–1487. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2009.02.007>.

22. Schumm J, Greulich S, Wagner A et al. Cardiovascular magnetic resonance risk stratification in patients with clinically suspected myocarditis. J Cardiovasc Magn Reson 2014; 16: 14. Dostupné z DOI: <http://dx.doi.org/10.1186/1532–429X-16–14>.

23. Lauer B, Niederau C, Kühl U et al. Cardiac troponin T in patients with clinically suspected myokarditis. J Am Coll Cardiol 1997; 30(5): 1354–1359.

24. Mahfoud F, Gärtner B, Kindermann M et al. Virus serology in patients with suspected myocarditis: utility or futility? Eur Heart J 2011; 32(7): 897–903. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehq493>.

25. Aretz HAT, Billingham ME, Edwards WD et al. Myocarditis. A histopathologic definition and classification. Am J Cardiovasc Pathol 1987; 1(1): 3–14.

26. Baughman KL. Diagnosis of myocarditis: Death of Dallas criteria. Circulation 2006; 113(4): 593–595.

27. Bock CT, Klingel K, Kandolf R. Human parvovirus B19-associated myocarditis. N Engl J Med 2010; 362(13): 1248–1249. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMc0911362>.

28. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129–2200. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw128>.

29. Krejci J, Hude P, Poloczkova H et al. Correlations of the changes in bioptic findings with echocardiographic, clinical and laboratory parameters in patients with inflammatory cardiomyopathy. Heart Vessels 2016; 31(3): 416–426. Dostupné z DOI: <http://dx.doi.org/10.1007/s00380–014–0618–0>.

30. Cooper LT, Berry GJ, Shabetai R. Idiopathic giant-cell myocarditis-natural history and treatment. Multicentre giant cell myocarditis study group investigators. N Engl J Med 1997; 336(26): 1860–1866.

31. Cooper LT, Hare JM, Tazelaar HD et al. Usefulness of immunosuppression for giant cell myocarditis. Am J Cardiol 2008; 102(11): 1535–1539. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2008.07.041>.

32. Kandolin R, Lehtonen J, Salmenkivi K et al. Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 2013; 6(1): 15–22. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.969261>.

33. Kawano S, Kato J, Kawano N et al. Clinical features and outcomes of eosinophilic myocarditis patients treated with prednisolone at a single institution over a 27-year period. Intern Med 2011; 50(9): 975–981.

34. Yanagisawa T, Inomata T, Watanabe I et al. Clinical significance of corticosteroid therapy for eosinophilic myocarditis. Int Heart J 2011; 52(2): 110–113.

35. Blauwet LA, Cooper LT. Idiopathic giant cell myocarditis and cardiac sarcoidosis. Heart Fail Rev 2013; 18(6): 733–746. Dostupné z DOI: <http://dx.doi.org/10.1007/s10741–012–9358–3>.

36. Cong L, Fang Q, Yafei Y et al. Immunosuppressive treatment for myocarditis: a meta-analysis of randomized controlled trials. J Cardiovasc Med (Hagerstown) 2016; 17(8): 631–637. Dostupné z DOI: <http://dx.doi.org/10.2459/JCM.0000000000000134>.

37. Gullestad L, Aass H, Fjeld JG et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation 2001; 103(2): 220–225.

38. Staudt A, Hummel A, Ruppert A et al. Immunoadsorption in dilated cardiomyopathy: 6-month results from randomized study. Am Heart J 2006; 152(4): 712.

39. Felix SB, Staudt A, Dörffer WV et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three-month results from a randomized study. J Am Coll Cardiol 2000; 35(6): 1590–1598.

40. McNamara DM, Holubkov R, Starling RC et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103(18): 2254–2259.

41. Kühl U, Pauschinger M, Schwimmbeck PL et al. Interferon-beta Treatment Eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107(22): 2793–2798.

42. Zimmermann O, Rodewald C, Radermacher M et al. Interferon β-1b therapy in chronic viral dilated cardiomyopathy – is there a role for specific therapy? J Cardiac Fail 2010; 16(4): 348–356. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cardfail.2009.12.016>.